Immune responses during COVID-19 infection
| Autor: | Florent Ginhoux, Agathe Dubuisson, Bertrand Gachot, Aymeric Silvin, Aurélien Marabelle, Imran Lahmar, Mauro Piacentini, Cléa Melenotte, Laurence Zitvogel, Guido Kroemer, Clémence Hénon, Lisa Derosa, Eric Solary, Michaela Fontenay, Didier Raoult, Fu-Sheng Wang, Markus Maeurer, Giuseppe Ippolito, Alimuddin Zumla, Mansouria Merad, Anne Gaëlle Goubet, Fabrice Andre |
|---|---|
| Přispěvatelé: | Gestionnaire, Hal Sorbonne Université, Institut Gustave Roussy (IGR), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Immunologie intégrative des tumeurs et immunothérapie des cancers (INTIM), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre d'Investigation Clinique en Biotherapie des cancers (CIC 1428 , CBT 507 ), Institut Gustave Roussy (IGR)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), University College of London [London] (UCL), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), University Medical Center [Mainz], Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), National Institute for Infectious Diseases 'Lazzaro Spallanzani', Università degli Studi di Roma Tor Vergata [Roma], Chinese Center for Disease Control and Prevention, Shanghai Jiao Tong University [Shanghai], Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Karolinska Institutet [Stockholm], Karolinska University Hospital [Stockholm], École Pratique des Hautes Études (EPHE), ANR-16-RHUS-0008,LUMIERE,LUMIERE(2016), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP) |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
viruses
Review medicine.disease_cause Diagnostic tools Severity of Illness Index [SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunity immune response humoral 0302 clinical medicine Risk Factors [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases Immunology and Allergy RC254-282 Coronavirus [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases Immunity Cellular [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases Neoplasms. Tumors. Oncology. Including cancer and carcinogens virus diseases 3. Good health Oncology Severe acute respiratory syndrome-related coronavirus [SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology 030220 oncology & carcinogenesis [SDV.IMM.IA] Life Sciences [q-bio]/Immunology/Adaptive immunology Middle East Respiratory Syndrome Coronavirus [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases Covid-19 Coronavirus disease 2019 (COVID-19) Sars-CoV-2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Immunology 03 medical and health sciences Immune system Intensive care medicine Humans [SDV.IMM.II] Life Sciences [q-bio]/Immunology/Innate immunity Host Microbial Interactions business.industry RC581-607 Protective Factors biochemical phenomena metabolism and nutrition medicine.disease immunity Immunity Humoral Clinical trial Middle East respiratory syndrome Immunologic diseases. Allergy business cellular 030215 immunology |
| Zdroj: | OncoImmunology OncoImmunology, 2020, 9 (1), pp.1807836. ⟨10.1080/2162402X.2020.1807836⟩ OncoImmunology, Taylor & Francis, 2020, 9 (1), pp.1807836. ⟨10.1080/2162402X.2020.1807836⟩ Oncoimmunology article-version (VoR) Version of Record OncoImmunology, Vol 9, Iss 1 (2020) |
| ISSN: | 2162-4011 2162-402X |
| Popis: | International audience; Over the past 16 years, three coronaviruses (CoVs), severe acute respiratory syndrome CoV (SARS-CoV) in 2002, Middle East respiratory syndrome CoV (MERS-CoV) in 2012 and 2015, and SARS-CoV-2 in 2020, have been causing severe and fatal human epidemics. The unpredictability of coronavirus disease-19 (COVID-19) poses a major burden on health care and economic systems across the world. This is caused by the paucity of in-depth knowledge of the risk factors for severe COVID-19, insufficient diagnostic tools for the detection of SARS-CoV-2, as well as the absence of specific and effective drug treatments. While protective humoral and cellular immune responses are usually mounted against these betacoronaviruses, immune responses to SARS-CoV2 sometimes derail towards inflammatory tissue damage, leading to rapid admissions to intensive care units. The lack of knowledge on mechanisms that tilt the balance between these two opposite outcomes poses major threats to many ongoing clinical trials dealing with immunostimulatory or immunoregulatory therapeutics. This review will discuss innate and cognate immune responses underlying protective or deleterious immune reactions against these pathogenic coronaviruses. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|